Hamon M, Doucet E, Lefèvre K, et al. (August 1999). „Antibodies and antisense oligonucleotide for probing the distribution and putative functions of central 5-HT6 receptors”. Neuropsychopharmacology21 (2 Suppl): 68S–76S. DOI:10.1016/S0893-133X(99)00044-5. PMID10432491.
Dawson LA, Nguyen HQ, Li P (November 2001). „The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus”. Neuropsychopharmacology25 (5): 662–8. DOI:10.1016/S0893-133X(01)00265-2. PMID11682249.
Schechter LE, Lin Q, Smith DL, et al. (May 2008). „Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466”. Neuropsychopharmacology33 (6): 1323–35. DOI:10.1038/sj.npp.1301503. PMID17625499.
Lacroix LP, Dawson LA, Hagan JJ, Heidbreder CA (February 2004). „5-HT6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex”. Synapse51 (2): 158–64. DOI:10.1002/syn.10288. PMID14618683.
Trani G, Baddeley SM, Briggs MA, Chuang TT, Deeks NJ, Johnson CN, Khazragi AA, Mead TL, Medhurst AD, Milner PH, Quinn LP, Ray AM, Rivers DA, Stean TO, Stemp G, Trail BK, Witty DR (October 2008). „Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists”. Bioorg. Med. Chem. Lett.18 (20): 5698–700. DOI:10.1016/j.bmcl.2008.08.010. PMID18793848.
Liu KG, Lo JR, Comery TA, Zhang GM, Zhang JY, Kowal DM, Smith DL, Di L, Kerns EH, Schechter LE, Robichaud AJ (February 2009). „Identification of a series of benzoxazoles as potent 5-HT6 ligands”. Bioorg. Med. Chem. Lett.19 (4): 1115–7. DOI:10.1016/j.bmcl.2008.12.107. PMID19152787.
Lee M, Rangisetty JB, Pullagurla MR, et al (2005). „1-(1-Naphthyl)piperazine as a novel template for 5-HT6 serotonin receptor ligands”. Bioorg. Med. Chem. Lett.15 (6): 1707–11. DOI:10.1016/j.bmcl.2005.01.031. PMID15745826.
Sikazwe D, Bondarev ML, Dukat M, Rangisetty JB, Roth BL, Glennon RA (2006). „Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors”. J. Med. Chem.49 (17): 5217–25. DOI:10.1021/jm060469q. PMID16913710.
Zhou P, Yan Y, Bernotas R, et al (2005). „4-(2-Aminoethoxy)-N-(phenylsulfonyl)indoles as novel 5-HT6 receptor ligands”. Bioorg. Med. Chem. Lett.15 (5): 1393–6. DOI:10.1016/j.bmcl.2005.01.005. PMID15713394.
Ahmed M, Briggs MA, Bromidge SM, et al (2005). „Bicyclic heteroarylpiperazines as selective brain penetrant 5-HT6 receptor antagonists”. Bioorg. Med. Chem. Lett.15 (21): 4867–71. DOI:10.1016/j.bmcl.2005.06.107. PMID16143522.
Alcalde E, Mesquida N, Frigola J, López-Pérez S, Mercè R (October 2008). „Indene-based scaffolds. Design and synthesis of novel serotonin 5-HT6 receptor ligands”. Org. Biomol. Chem.6 (20): 3795–810. DOI:10.1039/b808641a. PMID18843410.
Mattsson C, Sonesson C, Sandahl A, Greiner HE, Gassen M, Plaschke J, Leibrock J, Böttcher H (October 2005). „2-Alkyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles as novel 5-HT6 receptor agonists”. Bioorg. Med. Chem. Lett.15 (19): 4230–4. DOI:10.1016/j.bmcl.2005.06.067. PMID16055331.
Glennon RA, Lee M, Rangisetty JB, Dukat M, Roth BL, Savage JE, McBride A, Rauser L, Hufeisen S, Lee DK (2000). „2-Substituted tryptamines: agents with selectivity for 5-HT6 serotonin receptors”. J. Med. Chem.43 (5): 1011–8. DOI:10.1021/jm990550b. PMID10715164.
Cole DC, Stock JR, Lennox WJ, Bernotas RC, Ellingboe JW, Boikess S, Coupet J, Smith DL, Leung L, Zhang GM, Feng X, Kelly MF, Galante R, Huang P, Dawson LA, Marquis K, Rosenzweig-Lipson S, Beyer CE, Schechter LE (November 2007). „Discovery of N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine as a potent, selective, and orally active 5-HT(6) receptor agonist”. Journal of Medicinal Chemistry50 (23): 5535–8. DOI:10.1021/jm070521y. PMID17948978.
Alcalde E, Mesquida N, López-Pérez S, Frigola J, Mercè R (2009). „Indene-based scaffolds. 2. An indole-indene switch: discovery of novel indenylsulfonamides as 5-HT6 serotonin receptor agonists”. J. Med. Chem.52 (3): 675–87. DOI:10.1021/jm8009469. PMID19159187.
Hugerth A, Brisander M, Wrange U, Kritikos M, Norrlind B, Svensson M, Bisrat M, Ostelius J (February 2006). „Physical characterization of anhydrous and hydrous forms of the hydrochloride salt of BVT.5182 a novel 5-HT6 receptor antagonist”. Drug Dev Ind Pharm32 (2): 185–96. DOI:10.1080/03639040500466122. PMID16537199.
Heal DJ, Smith SL, Fisas A, Codony X, Buschmann H (February 2008). „Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders”. Pharmacol. Ther.117 (2): 207–31. DOI:10.1016/j.pharmthera.2007.08.006. PMID18068807.
Hamon M, Doucet E, Lefèvre K, et al. (August 1999). „Antibodies and antisense oligonucleotide for probing the distribution and putative functions of central 5-HT6 receptors”. Neuropsychopharmacology21 (2 Suppl): 68S–76S. DOI:10.1016/S0893-133X(99)00044-5. PMID10432491.
Dawson LA, Nguyen HQ, Li P (November 2001). „The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus”. Neuropsychopharmacology25 (5): 662–8. DOI:10.1016/S0893-133X(01)00265-2. PMID11682249.
Schechter LE, Lin Q, Smith DL, et al. (May 2008). „Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466”. Neuropsychopharmacology33 (6): 1323–35. DOI:10.1038/sj.npp.1301503. PMID17625499.
Lacroix LP, Dawson LA, Hagan JJ, Heidbreder CA (February 2004). „5-HT6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex”. Synapse51 (2): 158–64. DOI:10.1002/syn.10288. PMID14618683.
Trani G, Baddeley SM, Briggs MA, Chuang TT, Deeks NJ, Johnson CN, Khazragi AA, Mead TL, Medhurst AD, Milner PH, Quinn LP, Ray AM, Rivers DA, Stean TO, Stemp G, Trail BK, Witty DR (October 2008). „Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists”. Bioorg. Med. Chem. Lett.18 (20): 5698–700. DOI:10.1016/j.bmcl.2008.08.010. PMID18793848.
Liu KG, Lo JR, Comery TA, Zhang GM, Zhang JY, Kowal DM, Smith DL, Di L, Kerns EH, Schechter LE, Robichaud AJ (February 2009). „Identification of a series of benzoxazoles as potent 5-HT6 ligands”. Bioorg. Med. Chem. Lett.19 (4): 1115–7. DOI:10.1016/j.bmcl.2008.12.107. PMID19152787.
Lee M, Rangisetty JB, Pullagurla MR, et al (2005). „1-(1-Naphthyl)piperazine as a novel template for 5-HT6 serotonin receptor ligands”. Bioorg. Med. Chem. Lett.15 (6): 1707–11. DOI:10.1016/j.bmcl.2005.01.031. PMID15745826.
Sikazwe D, Bondarev ML, Dukat M, Rangisetty JB, Roth BL, Glennon RA (2006). „Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors”. J. Med. Chem.49 (17): 5217–25. DOI:10.1021/jm060469q. PMID16913710.
Zhou P, Yan Y, Bernotas R, et al (2005). „4-(2-Aminoethoxy)-N-(phenylsulfonyl)indoles as novel 5-HT6 receptor ligands”. Bioorg. Med. Chem. Lett.15 (5): 1393–6. DOI:10.1016/j.bmcl.2005.01.005. PMID15713394.
Ahmed M, Briggs MA, Bromidge SM, et al (2005). „Bicyclic heteroarylpiperazines as selective brain penetrant 5-HT6 receptor antagonists”. Bioorg. Med. Chem. Lett.15 (21): 4867–71. DOI:10.1016/j.bmcl.2005.06.107. PMID16143522.
Alcalde E, Mesquida N, Frigola J, López-Pérez S, Mercè R (October 2008). „Indene-based scaffolds. Design and synthesis of novel serotonin 5-HT6 receptor ligands”. Org. Biomol. Chem.6 (20): 3795–810. DOI:10.1039/b808641a. PMID18843410.
Mattsson C, Sonesson C, Sandahl A, Greiner HE, Gassen M, Plaschke J, Leibrock J, Böttcher H (October 2005). „2-Alkyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles as novel 5-HT6 receptor agonists”. Bioorg. Med. Chem. Lett.15 (19): 4230–4. DOI:10.1016/j.bmcl.2005.06.067. PMID16055331.
Glennon RA, Lee M, Rangisetty JB, Dukat M, Roth BL, Savage JE, McBride A, Rauser L, Hufeisen S, Lee DK (2000). „2-Substituted tryptamines: agents with selectivity for 5-HT6 serotonin receptors”. J. Med. Chem.43 (5): 1011–8. DOI:10.1021/jm990550b. PMID10715164.
Cole DC, Stock JR, Lennox WJ, Bernotas RC, Ellingboe JW, Boikess S, Coupet J, Smith DL, Leung L, Zhang GM, Feng X, Kelly MF, Galante R, Huang P, Dawson LA, Marquis K, Rosenzweig-Lipson S, Beyer CE, Schechter LE (November 2007). „Discovery of N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine as a potent, selective, and orally active 5-HT(6) receptor agonist”. Journal of Medicinal Chemistry50 (23): 5535–8. DOI:10.1021/jm070521y. PMID17948978.
Alcalde E, Mesquida N, López-Pérez S, Frigola J, Mercè R (2009). „Indene-based scaffolds. 2. An indole-indene switch: discovery of novel indenylsulfonamides as 5-HT6 serotonin receptor agonists”. J. Med. Chem.52 (3): 675–87. DOI:10.1021/jm8009469. PMID19159187.
Hugerth A, Brisander M, Wrange U, Kritikos M, Norrlind B, Svensson M, Bisrat M, Ostelius J (February 2006). „Physical characterization of anhydrous and hydrous forms of the hydrochloride salt of BVT.5182 a novel 5-HT6 receptor antagonist”. Drug Dev Ind Pharm32 (2): 185–96. DOI:10.1080/03639040500466122. PMID16537199.
Heal DJ, Smith SL, Fisas A, Codony X, Buschmann H (February 2008). „Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders”. Pharmacol. Ther.117 (2): 207–31. DOI:10.1016/j.pharmthera.2007.08.006. PMID18068807.
Ivachtchenko AV, Frolov EB, Mitkin OD, Kysil VM, Khvat AV, Okun IM, Tkachenko SE (June 2009). „Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists”. Bioorganic & Medicinal Chemistry Letters19 (12): 3183–7. DOI:10.1016/j.bmcl.2009.04.128. PMID19443217.
Liu KG, Robichaud AJ, Bernotas RC, Yan Y, Lo JR, Zhang MY, Hughes ZA, Huselton C, Zhang GM, Zhang JY, Kowal DM, Smith DL, Schechter LE, Comery TA (2010). „5-Piperazinyl-3-sulfonylindazoles as potent and selective 5-hydroxytryptamine-6 antagonists”. J Med Chem.53 (21): 7639-46. PMID20932009.
